Crinetics Pharmaceuticals Inc
CRNX48.042USD
-0.668-1.37%
Market hours （ET）Quotes delayed by 15 min
4.54BMarket Cap
LossP/E TTM
More Details of Crinetics Pharmaceuticals Inc Company
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Crinetics Pharmaceuticals Inc Info
Ticker SymbolCRNX
Company nameCrinetics Pharmaceuticals Inc
IPO dateJul 18, 2018
CEOStruthers (R. Scott)
Number of employees437
Security typeOrdinary Share
Fiscal year-endJul 18
Address6055 Lusk Blvd.
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18584506464
Websitehttps://www.crinetics.com/
Ticker SymbolCRNX
IPO dateJul 18, 2018
CEOStruthers (R. Scott)
Company Executives of Crinetics Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
16.30K
+73.40%
Dr. Dana Pizzuti, M.D.
Dr. Dana Pizzuti, M.D.
Chief Medical and Development Officer
Chief Medical and Development Officer
--
--
Ms. Isabel Kalofonos
Ms. Isabel Kalofonos
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.21%
The Vanguard Group, Inc.
9.64%
Wellington Management Company, LLP
8.83%
BlackRock Institutional Trust Company, N.A.
7.01%
Driehaus Capital Management, LLC
6.83%
Other
54.47%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.21%
The Vanguard Group, Inc.
9.64%
Wellington Management Company, LLP
8.83%
BlackRock Institutional Trust Company, N.A.
7.01%
Driehaus Capital Management, LLC
6.83%
Other
54.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.18%
Investment Advisor/Hedge Fund
43.98%
Hedge Fund
14.23%
Individual Investor
2.02%
Venture Capital
2.01%
Research Firm
1.94%
Private Equity
1.16%
Bank and Trust
0.57%
Pension Fund
0.49%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
525
110.25M
122.53%
+10.44K
2025Q3
543
110.25M
126.46%
+2.35M
2025Q2
527
106.83M
124.47%
+1.78M
2025Q1
508
105.21M
122.53%
-8.81M
2024Q4
492
102.43M
107.05%
+15.47M
2024Q3
460
87.33M
121.15%
+1.87M
2024Q2
441
84.74M
119.85%
+1.98M
2024Q1
399
82.75M
110.72%
-4.21M
2023Q4
366
73.18M
119.64%
+1.80M
2023Q3
342
72.45M
96.67%
+14.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
12.42M
13.19%
+97.46K
+0.79%
Jun 30, 2025
The Vanguard Group, Inc.
9.24M
9.81%
-55.47K
-0.60%
Jun 30, 2025
Wellington Management Company, LLP
5.81M
6.17%
-1.08M
-15.73%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.50M
6.9%
-274.52K
-4.05%
Jun 30, 2025
Driehaus Capital Management, LLC
6.40M
6.8%
+160.12K
+2.57%
Jun 30, 2025
Farallon Capital Management, L.L.C.
5.63M
5.97%
+979.00K
+21.07%
Aug 29, 2025
T. Rowe Price Associates, Inc.
5.49M
5.83%
+472.19K
+9.40%
Jun 30, 2025
EcoR1 Capital, LLC
4.29M
4.55%
--
--
Jun 30, 2025
Janus Henderson Investors
3.41M
3.62%
-14.12K
-0.41%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.34M
2.49%
+397.38K
+20.42%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
3.24%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.92%
Tema Heart & Health ETF
1.9%
ALPS Medical Breakthroughs ETF
1.79%
iShares U.S. Pharmaceuticals ETF
1.51%
First Trust Multi-Manager Small Cap Opportunities ETF
1.31%
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
ProShares Ultra Nasdaq Biotechnology
0.52%
Invesco Nasdaq Biotechnology ETF
0.4%
iShares Biotechnology ETF
0.34%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion3.24%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.92%
Tema Heart & Health ETF
Proportion1.9%
ALPS Medical Breakthroughs ETF
Proportion1.79%
iShares U.S. Pharmaceuticals ETF
Proportion1.51%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion1.31%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.92%
ProShares Ultra Nasdaq Biotechnology
Proportion0.52%
Invesco Nasdaq Biotechnology ETF
Proportion0.4%
iShares Biotechnology ETF
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Crinetics Pharmaceuticals Inc?
The top five shareholders of Crinetics Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC holds 12.42M shares, accounting for 13.19% of the total shares.
The Vanguard Group, Inc. holds 9.24M shares, accounting for 9.81% of the total shares.
Wellington Management Company, LLP holds 5.81M shares, accounting for 6.17% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.50M shares, accounting for 6.90% of the total shares.
Driehaus Capital Management, LLC holds 6.40M shares, accounting for 6.80% of the total shares.
Fidelity Management & Research Company LLC holds 12.42M shares, accounting for 13.19% of the total shares.
The Vanguard Group, Inc. holds 9.24M shares, accounting for 9.81% of the total shares.
Wellington Management Company, LLP holds 5.81M shares, accounting for 6.17% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.50M shares, accounting for 6.90% of the total shares.
Driehaus Capital Management, LLC holds 6.40M shares, accounting for 6.80% of the total shares.
What are the top three shareholder types of Crinetics Pharmaceuticals Inc?
The top three shareholder types of Crinetics Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Wellington Management Company, LLP
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Wellington Management Company, LLP
How many institutions hold shares of Crinetics Pharmaceuticals Inc (CRNX)?
As of 2025Q4, 525 institutions hold shares of Crinetics Pharmaceuticals Inc, with a combined market value of approximately 110.25M, accounting for 122.53% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.93%.
What is the biggest source of revenue for Crinetics Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Crinetics Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
